NRx Pharmaceuticals, Inc. $NRXP Shares Purchased by Anson Funds Management LP

Key Points

• Anson Funds Management LP increased its holdings in NRx Pharmaceuticals by 535.1%, acquiring over 993,401 shares in the first quarter, bringing its total to approximately $2.42 million.
• NRx Pharmaceuticals reported disappointing earnings, with an EPS of ($0.98) for the latest quarter, missing analysts' estimates by ($0.67).
• Analysts have mixed views on NRx Pharmaceuticals, with a consensus average rating of "Buy" and an average target price of $28.50.

Anson Funds Management LP grew its position in NRx Pharmaceuticals, Inc. (NASDAQ:NRXP - Free Report) by 535.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,179,061 shares of the company's stock after purchasing an additional 993,401 shares during the period. Anson Funds Management LP owned about 6.85% of NRx Pharmaceuticals worth $2,417,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of NRXP. Sassicaia Capital Advisers LLC purchased a new position in shares of NRx Pharmaceuticals during the fourth quarter worth approximately $33,000. Squarepoint Ops LLC purchased a new stake in NRx Pharmaceuticals in the 4th quarter worth approximately $56,000. Millennium Management LLC purchased a new stake in NRx Pharmaceuticals during the 4th quarter valued at approximately $61,000. Finally, AdvisorShares Investments LLC grew its holdings in shares of NRx Pharmaceuticals by 138.5% in the fourth quarter. AdvisorShares Investments LLC now owns 310,314 shares of the company's stock valued at $683,000 after purchasing an additional 180,229 shares in the last quarter. 4.27% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have commented on NRXP shares. D. Boral Capital reaffirmed a "buy" rating and set a $31.00 price objective on shares of NRx Pharmaceuticals in a research note on Tuesday, August 19th. BTIG Research reaffirmed a "buy" rating on shares of NRx Pharmaceuticals in a research note on Monday. Finally, Wall Street Zen raised shares of NRx Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. One analyst has rated the stock with a Strong Buy rating and four have given a Buy rating to the stock. According to MarketBeat, NRx Pharmaceuticals currently has an average rating of "Buy" and an average price target of $28.50.

NRx Pharmaceuticals Price Performance

NRx Pharmaceuticals stock traded down $0.25 during trading hours on Friday, reaching $2.27. The stock had a trading volume of 417,118 shares, compared to its average volume of 504,896. The company has a market cap of $44.97 million, a price-to-earnings ratio of -1.01 and a beta of 1.59. The business's 50 day moving average price is $2.92 and its 200-day moving average price is $2.55. NRx Pharmaceuticals, Inc. has a 52 week low of $1.10 and a 52 week high of $6.01.

NRx Pharmaceuticals (NASDAQ:NRXP - Get Free Report) last announced its earnings results on Monday, August 18th. The company reported ($0.98) EPS for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.67). On average, sell-side analysts forecast that NRx Pharmaceuticals, Inc. will post -1.75 EPS for the current fiscal year.

NRx Pharmaceuticals Profile

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.